Market Overview

UPDATE: Benchmark Company Reiterates Speculative Buy Rating, Lowers PT on Chembio Diagnostics

Related CEMI
Zacks Rank #1 Additions for Tuesday - Tale of the Tape
Chembio Terminates U.S. Distribution Agreement With Alere

In a report published Wednesday, Benchmark Company reiterated its Speculative Buy rating on Chembio Diagnostics (NASDAQ: CEMI), but lowered its price target from $14.00 to $10.00.

Benchmark noted, “Order volumes have been lumpy with Q4 reportedly benefiting from a record backlog at the expense of Q3 results. Most important, Management disclosed it believes its DPP HIV test successfully concluded its FDA pre-approval inspection during October. We anticipate this is the last significant hurdle prior to FDA marketing clearance likely in December of January. This DPP-HIV test is the first of at least three significant new rapid diagnostics that Chembio is developing to target syphilis, HIV and hepatitis-C (HCV) over the 2013-2015 timeframe. We are increasingly optimistic in this pipeline but based on diminished recent results we trimmed our out-year EPS forecast and cut our price target to $10, from $14.”

Chembio Diagnostics closed on Tuesday at $4.12.

Posted-In: Benchmark CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (CEMI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters